drugset / Trial / NCT00246987
A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
RandomizedParallel-groupDouble-blindTreatment
Summary
To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Muraglitazar | Small molecule | 2.5 mg | — |
| Subject | Muraglitazar | Small molecule | 5 mg | — |